BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Callan Family Office LLC

Callan Family Office LLC lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 239.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,038 shares of the biotechnology company’s stock after purchasing an additional 47,264 shares during the period. Callan Family Office LLC’s holdings in BioMarin Pharmaceutical were worth $3,685,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Blair William & Co. IL lifted its stake in shares of BioMarin Pharmaceutical by 9.0% in the 2nd quarter. Blair William & Co. IL now owns 5,232 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 432 shares during the period. Vontobel Holding Ltd. lifted its stake in shares of BioMarin Pharmaceutical by 68.1% in the 2nd quarter. Vontobel Holding Ltd. now owns 7,901 shares of the biotechnology company’s stock valued at $434,000 after purchasing an additional 3,202 shares during the period. Louisiana State Employees Retirement System increased its holdings in BioMarin Pharmaceutical by 1.1% in the 2nd quarter. Louisiana State Employees Retirement System now owns 54,000 shares of the biotechnology company’s stock worth $2,968,000 after acquiring an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS increased its holdings in BioMarin Pharmaceutical by 1.7% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 70,537 shares of the biotechnology company’s stock worth $3,877,000 after acquiring an additional 1,200 shares in the last quarter. Finally, QRG Capital Management Inc. purchased a new stake in BioMarin Pharmaceutical in the 2nd quarter worth $301,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on BMRN shares. Raymond James Financial started coverage on shares of BioMarin Pharmaceutical in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $85.00 price target for the company. Wolfe Research set a $95.00 price target on shares of BioMarin Pharmaceutical and gave the stock an “outperform” rating in a report on Tuesday, July 15th. Wall Street Zen lowered shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday. Morgan Stanley cut their price target on shares of BioMarin Pharmaceutical from $97.00 to $96.00 and set an “overweight” rating for the company in a report on Tuesday, July 22nd. Finally, Wedbush reissued an “outperform” rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $93.26.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $52.32 on Friday. BioMarin Pharmaceutical Inc. has a 52-week low of $51.78 and a 52-week high of $73.51. The firm has a market capitalization of $10.05 billion, a price-to-earnings ratio of 15.53, a PEG ratio of 0.68 and a beta of 0.33. The company has a fifty day simple moving average of $56.37 and a 200-day simple moving average of $58.19. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.